Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study

IF 12.9 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Magnus Holmer, Michael Ingre, Martti Färkkilä, Cyriel Ponsioen, Bregje Mol, Christoph Schramm, Trine Folseraas, Kristine Wiencke, Nora Cazzagon, Elisa Catanzaro, Antonio Molinaro, Emma Nilsson, Johan Vessby, Stergios Kechagias, Nils Nyhlin, Mårten Werner, Annika Bergquist
{"title":"Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study","authors":"Magnus Holmer, Michael Ingre, Martti Färkkilä, Cyriel Ponsioen, Bregje Mol, Christoph Schramm, Trine Folseraas, Kristine Wiencke, Nora Cazzagon, Elisa Catanzaro, Antonio Molinaro, Emma Nilsson, Johan Vessby, Stergios Kechagias, Nils Nyhlin, Mårten Werner, Annika Bergquist","doi":"10.1097/hep.0000000000001351","DOIUrl":null,"url":null,"abstract":"Background &amp; Aims The risk of hepatocellular carcinoma (HCC) in primary sclerosing cholangitis (PSC) is unclear. Studies indicate a low risk for HCC questioning the rationale for current HCC surveillance guidelines. This study explores the risk of HCC in a longitudinal multicenter cohort with over 3.000 PSC-subjects. Approach &amp; results Subjects with well characterized PSC (n=3.071) were followed at 12 university hospitals within the International PSC registry (IPSCR) collaboration for a total of 38,387 person-years. Incident HCC was registered. Subjects were followed from PSC-diagnosis until death, liver transplantation, diagnosis of hepatobiliary malignancy, or February 2024. <jats:italic toggle=\"yes\">Poisson</jats:italic> regression was used to calculate incidence rate ratios for HCC for the total population and for subgroups of different ages and cirrhosis status. Thirty-nine subjects developed HCC after a mean time of 16.4 years (SD ±10.7) from PSC diagnosis. In 26 (66.7%) of HCC cases, cirrhosis was diagnosed before HCC. The mean age at HCC diagnosis was 55.6 years (±SD13.1 years) and 28 (71.8%) were male. HCC was associated with cirrhosis (IRR 10.8;95%CI=5.7-20.5) and age (IRR 1.05;95%CI=1.03-1.08). At the age 50, the incidence rate was 0.81 and 0.47 for cirrhotic men and women respectively. For non-cirrhotic subjects, the risk was low for both men and women and all age groups. Conclusion Hepatocellular carcinoma is relatively rare in patients with primary sclerosing cholangitis who do not have cirrhosis, especially in those under the age of 50. Our findings indicate that HCC monitoring for patients with PSC can be tailored, based on their age and cirrhosis status.","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"74 1 1","pages":""},"PeriodicalIF":12.9000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/hep.0000000000001351","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background & Aims The risk of hepatocellular carcinoma (HCC) in primary sclerosing cholangitis (PSC) is unclear. Studies indicate a low risk for HCC questioning the rationale for current HCC surveillance guidelines. This study explores the risk of HCC in a longitudinal multicenter cohort with over 3.000 PSC-subjects. Approach & results Subjects with well characterized PSC (n=3.071) were followed at 12 university hospitals within the International PSC registry (IPSCR) collaboration for a total of 38,387 person-years. Incident HCC was registered. Subjects were followed from PSC-diagnosis until death, liver transplantation, diagnosis of hepatobiliary malignancy, or February 2024. Poisson regression was used to calculate incidence rate ratios for HCC for the total population and for subgroups of different ages and cirrhosis status. Thirty-nine subjects developed HCC after a mean time of 16.4 years (SD ±10.7) from PSC diagnosis. In 26 (66.7%) of HCC cases, cirrhosis was diagnosed before HCC. The mean age at HCC diagnosis was 55.6 years (±SD13.1 years) and 28 (71.8%) were male. HCC was associated with cirrhosis (IRR 10.8;95%CI=5.7-20.5) and age (IRR 1.05;95%CI=1.03-1.08). At the age 50, the incidence rate was 0.81 and 0.47 for cirrhotic men and women respectively. For non-cirrhotic subjects, the risk was low for both men and women and all age groups. Conclusion Hepatocellular carcinoma is relatively rare in patients with primary sclerosing cholangitis who do not have cirrhosis, especially in those under the age of 50. Our findings indicate that HCC monitoring for patients with PSC can be tailored, based on their age and cirrhosis status.
肝硬化和年龄是原发性硬化性胆管炎患者HCC风险的关键决定因素:一项多中心纵向队列研究
背景,目的原发性硬化性胆管炎(PSC)发生肝细胞癌(HCC)的风险尚不清楚。研究表明HCC的低风险对当前HCC监测指南的合理性提出了质疑。本研究对3000多名psc患者进行了纵向多中心队列研究,探讨了HCC的风险。的方法,结果在国际PSC注册(IPSCR)合作的12所大学医院中,对PSC特征明确的受试者(n=3.071)进行了随访,共38,387人年。记录HCC事件。受试者从psc诊断至死亡、肝移植、诊断为肝胆恶性肿瘤,或2024年2月随访。泊松回归用于计算总体人群以及不同年龄和肝硬化状态亚组的HCC发病率比。39名受试者在PSC诊断后平均16.4年(SD±10.7)发生HCC。26例(66.7%)HCC患者在HCC前诊断为肝硬化。HCC诊断的平均年龄为55.6岁(±SD13.1岁),男性28例(71.8%)。HCC与肝硬化(IRR 10.8;95%CI=5.7-20.5)和年龄(IRR 1.05;95%CI=1.03-1.08)相关。在50岁时,肝硬化男性和女性的发病率分别为0.81和0.47。对于非肝硬化受试者,男性和女性以及所有年龄组的风险都很低。结论原发性硬化性胆管炎患者发生肝细胞癌相对少见,尤其是50岁以下患者。我们的研究结果表明,PSC患者的HCC监测可以根据他们的年龄和肝硬化状况进行定制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Hepatology
Hepatology 医学-胃肠肝病学
CiteScore
27.50
自引率
3.70%
发文量
609
审稿时长
1 months
期刊介绍: HEPATOLOGY is recognized as the leading publication in the field of liver disease. It features original, peer-reviewed articles covering various aspects of liver structure, function, and disease. The journal's distinguished Editorial Board carefully selects the best articles each month, focusing on topics including immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases, liver cancer, and drug metabolism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信